XML 22 R11.htm IDEA: XBRL DOCUMENT

Marketable Securities

3 Months Ended

Mar. 31, 2021

Marketable Securities

Marketable Securities

5. Marketable and Equity Securities

The Company’s marketable debt securities held as of March 31, 2021 and December 31, 2020 are summarized below:


					Gross			Gross
		Amortized			Unrealized			Unrealized
March 31, 2021		Cost			Gains			Losses			Fair Value
(in thousands)
Money Market Funds		$	165,350		$	—		$	—		$	165,350
Corporate Securities			73,922			12			(5)			73,929
Government Securities			319,931			107			(7)			320,031
		$	559,203		$	119		$	(12)		$	559,310

Reported as
Cash and cash equivalents											$	165,350
Marketable securities												393,960
Total investments											$	559,310



					Gross			Gross
		Amortized			Unrealized			Unrealized
December 31, 2020		Cost			Gains			Losses			Fair Value
(in thousands)
Money Market Funds		$	158,937		$	—		$	—		$	158,937
Corporate Securities			119,782			57			(6)			119,833
Government Securities			315,319			37			(3)			315,353
		$	594,038		$	94		$	(9)		$	594,123

Reported as
Cash and cash equivalents											$	158,937
Marketable securities												435,186
Total investments											$	594,123

The maturities of the Company’s marketable debt securities are as follows:


		Amortized			Estimated
March 31, 2021		Cost			Fair Value
(in thousands)
Mature in one year or less		$	368,762		$	368,878
Mature within two years			25,091			25,082
		$	393,853		$	393,960

The unrealized losses on available-for-sale investments and their related fair values as of March 31, 2021 and December 31, 2020 are as follows:


		Less than 12 months						12 months or greater
					Unrealized						Unrealized
March 31, 2021		Fair value			losses			Fair value			losses
(in thousands)
Corporate Securities		$	4,102		$	(2)		$	3,066		$	(3)
Government Securities			—			—			14,990			(7)
		$	4,102		$	(2)		$	18,056		$	(10)



		Less than 12 months						12 months or greater
					Unrealized						Unrealized
December 31, 2020		Fair value			losses			Fair value			losses
(in thousands)
Corporate Securities		$	15,843		$	(6)		$	—		$	—
Government Securities			40,802			(3)			—			—
		$	56,645		$	(9)		$	—		$	—

The unrealized losses from the listed securities are primarily due to a change in the interest rate environment and not a change in the credit quality of the securities.

In 2020, the Company received shares of common stock of Aimmune Therapeutics, Inc. (Aimmune) and shares of common stock of Viridian Therapeutics, Inc. (Viridian, formerly MiRagen Therapeutics, Inc.) in connection with the Aimmune and Viridian licensing arrangements (both as defined below). The Aimmune common stock was redeemed for cash within the same year; the Viridian common stock is classified as equity securities with a readily determinable fair value at March 31, 2021. In 2020, the Company also received equity of Zenas BioPharma Limited (Zenas), a private company, in connection with a licensing agreement. The Company elected the measurement alternative to carry the Zenas equity at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There has not been any impairment or observable price changes related to this investment. In 2018, the Company received equity shares in Quellis Biosciences, Inc. (Quellis), a private company, in connection with a licensing transaction. The Company recorded the Quellis equity as securities not having a readily determinable fair value, and the investment was recorded at its original cost. In 2021, Quellis merged into Catabasis Pharmaceuticals, Inc. (Catabasis), and the Company received equity shares in Catabasis, which common shares have a readily determinable fair value. The adjustment in the fair value of the Catabasis equity has been recorded in other income (loss) for the three months ended March 31, 2021.

Net gains and losses during the year ended March 31, 2021 and 2020 consist of the following:


		Three Months Ended
		March 31,
		2021			2020
Net gains (losses) recognized on equity securities		$	12,981		$	(2,336)
Less: net gains recognized on equity securities redeemed			(1)			—
Unrealized gains (losses) recognized on equity securities		$	12,980		$	(2,336)